Coronavirus Notebook: Vaccine Approvals In India Amid Wins And Losses For Drug Developers In China
India has issued emergency approvals for a number of new COVID-19 vaccines and extended eligible age groups for others, while developers of potential drug therapies in China have seen both gains and setbacks.
You may also be interested in...
Also, AstraZeneca presents more promising data for its COVID-19 antibody cocktail Evusheld and Novavax says its vaccine is able to neutralize the Omicron variant.
Ocugen’s mutation-agnostic candidate for retinitis pigmentosa and leber congenital amaurosis is set for Phase I trials in the US. In this exclusive audio interview, founder and CEO Shankar Musunuri speaks to Scrip about seeking partners beyond CanSino Biologics for the candidate while stressing Bharat Biotech’s COVID-19 vaccine could hold promise against the Omicron variant.
The WHO has granted an emergency listing to Novavax's COVID-19 vaccine, paving the way for wider use along with a new approval in the EU this week. The protein-based product has also just been filed in Japan, where Moderna's mRNA shot has been newly cleared for booster use.